Lightbridge (LTBR) Q4 2022 earnings summary

Executive summary

• Pre-revenue nuclear-fuel development program advanced through INL agreements, PNNL casting work and DOE-supported research; commercialization remains dependent on funding, testing and regulatory approval.

• 2022 net loss was $7.5 million; cash and cash equivalents ended the year at $28.9 million, with no debt.

Financial highlights

• Revenue was $0 in 2022 and 2021; net loss was $7.5 million versus $7.8 million, and operating loss was $7.8 million versus $7.9 million.

• G&A expense rose to $7.5 million from $7.2 million; R&D expense declined to $0.7 million from $1.4 million.

• Interest income increased to $0.3 million from $0.03 million; 2022 basic and diluted loss per share was $0.69 versus $1.71 in 2021.

• Cash used in operations was $6.8 million in 2022 versus $11.0 million in 2021; the prior-year outflow included a $4.2 million arbitration settlement payment.

Outlook and guidance

• Management expected cash resources to cover operating needs for the next 12 months; projected total spending for the next 12–15 months was $13.1–$15.7 million, including ~$6.5 million for R&D.

• Fuel material coupons were expected to enter the ATR in 2025, with irradiation and post-irradiation examination taking ~4 years; lead test assemblies are targeted for commercial reactors in the 2030s.

• Initial commercial fuel reload orders are estimated 15–20 years away, assuming adequate R&D funding; commercialization timing and costs remain highly uncertain.

• Long-term outside R&D spending is projected to average $10 million annually over 10–15 years, requiring future government support.